NCT00276510

A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints

Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2,878 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type.

Conditions

• Memory Disorders, Age-Related
• Retention Disorders, Cognitive

Interventions

Type	Name	Description
DRUG	EGb 761® (Tanakan®)	120 mg, 1 tablet twice a day, oral route, during 5 years.
OTHER	Placebo	1 tablet twice a day, oral route, during 5 years.

Timeline

• Start date: 2002-02-01
• Primary completion: 2009-11-01
• Completion: 2009-11-01
• First posted: 2006-01-13
• Last updated: 2019-01-15

Locations

698 sites across 1 country: France